CTRI/2009/091/001022已完成3 期
An open label multicentric study to assess the efficacy and safety of Atorvastatin + Ramipril + Aspirin + Metoprolol (as extended release) fixed dose combination capsules for secondary prophylaxis in patients with ischemic heart disease.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 4
- 主要终点
- No. of events of manifestations of ischemic heart disease experienced by the patients during the study period of 4 weeks.
研究概览
简要总结
This study is an open label, multicentric study assessing the safety and efficacy of fixed-dose combination capsules of Atorvastatin 10mg + Ramipril 5mg + Aspirin 150mg + Metoprolol succinate 25mg (as extended release) once daily in the evening for 4 weeks for secondary prophylaxis in 100 patients with ischemic heart disease that will be conducted in one center only in India. The primary outcome measure will be the number of events of manifestations of ischemic heart disease experienced by the patients during the study period of 4 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Open Label
入排标准
- 年龄范围
- 18.00 Year(s) 至 99.00 Year(s)（—）
- 性别
- All
入选标准
- •1.Patients of either sex more than or equal to 18 years of age (No upper age limit was mentioned in our Protocol for this clinical trial).
- •2.Established diagnosis of ischemic heart disease.
- •3.Informed consent of the patient / relative.
排除标准
- •1.Pregnancy & Lactation.
- •2.Patients with active liver disease or hepatic dysfunction indicated by AST or ALT levels 2.5 times the upper limit of normal.
- •3.Patients with history of myopathy or evidence of active muscle disease.
- •4.Patients with congestive heart failure (defined as New York Heart Association class III or IV heart failure).
- •5.Patients with 2nd or 3rd degree AV block, sick sinus syndrome or uncontrolled cardiac arrhythmias.
- •6.Patients with active peptic ulceration, hemophilia or hemorrhagic disorders.
- •7.Patients with unstable endocrine or metabolic diseases known to influence serum lipids and lipoproteins or known impairment of renal function.
- •8.Patients with any other serious concurrent illness or malignancy.
- •9.Patients with continuing history of alcohol and / or drug abuse.
- •10.Patients with known hypersensitivity to either of the contents of the combination.
结局指标
主要结局
No. of events of manifestations of ischemic heart disease experienced by the patients during the study period of 4 weeks.
时间窗: 0,2 & 4 weeks.
次要结局
- (1)The reduction in the systolic and diastolic blood pressure at the end of the treatment phase i.e. Week 4, as compared to the start of the treatment phase i.e., Week 0.((2)The percent change in serum LDL cholesterol and other lipid parameters at the end of the treatment phase i.e., Week 4, as compared to the start of the treatment phase i.e., Week 0.)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
3 期
A clinical trial to study the efficacy and safety of fixed dose combination of a proton pump inhibitor and a dopamine antagonist in the treatment of gastroesophageal reflux disease.CTRI/2012/03/002508Sun Pharmaceutical Industries Ltd200
尚未招募
3 期
A clinical trial to study the efficacy and safety of fixed dose combination in the treatment of gastroesophageal reflux disease.CTRI/2012/04/002575Sun Pharmaceutical Industries Ltd200
终止
2 期
Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung CancerLung Neoplasm MalignantNCT02985203Guangdong Association of Clinical Trials45
已完成
3 期
A clinical trial to study the effects of two drugs, fixed dose combination capsules of Celecoxib and Diacerein and fixed dose combination tablets of Aceclofenac and Diacerein in patients with osteoarthritis of knee and/or hip joints.CTRI/2010/091/000053Cadila Healthcare Ltd200
招募中
1 期
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMMRelapsed and/or Refractory Multiple MyelomaNCT06182696OriCell Therapeutics Co., Ltd.83